IQVIA Holdings (IQV) - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US46266C1053

(NYSE:IQV Stock) IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and decentralized clinical trials, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was incorporated in 2016 and is headquartered in Durham, North Carolina. Web URL:

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for IQVIA Holdings (IQV) - Stock Price & Dividends

IQV Stock Overview

Market Cap in USD 44,190m
Sector Healthcare
Industry Diagnostics & Research
GiC SubIndustry Life Sciences Tools & Services
TER 0.00%
IPO / Inception 2013-05-09

IQV Stock Ratings

Fundamental 1.98
Dividend -
Growth 5y 4.27
Rel. Performance vs Sector -0.37
Analysts 4.60
Fair Price Total Ret. 227.33
Fair Price DCF 195.60

IQV Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

IQV Growth Ratios

Growth 12m 12.46%
Growth Correlation 12m 26%
Growth Correlation 3m 16%
CAGR 5y 10.83%
CAGR / Mean Drawdown 0.79
Sharpe Ratio 12m 0.26
Alpha vs SP500 12m -23.19
Beta vs SP500 5y weekly 1.42
CAPM 9.17%
Average Daily Range 2m 2.47%
Regime Oscillator 91.39
Volatility GJR Garch 1y 27.60%
Price / SMA 50 7.1%
Price / SMA 200 12.34%
Current Volume 1186.1k
Average Volume 20d 1159.6k

External Links for IQV Stock

Wall Street JournalBenzingaYahoo Finance
X (Twitter)Stocktwits
Fund Manager Positions
What is the price of IQV stocks?
As of February 22, 2024, the stock is trading at USD 237.28 with a total of 1,186,096 shares traded.
Over the past week, the price has changed by -2.54%, over one month by +8.97%, over three months by +14.38% and over the past year by +11.41%.
Why is IQV stock down?
Check with which Index or Commodity IQV has the highest Correlation, do they have a common driver?
Review the Fundamentals to find weaknesses (Debt, low returns). Check the Performance of the Peer-Group to find out, if the entire sector is under pressure.
Period Return IQV Return S&P 500
1 Month 8.97% 2.85%
3 Months 14.38% 10.14%
12 Months 11.41% 26.48%
What is the forecast for IQV stock price target?
According to ValueRays Forecast Model, IQV IQVIA Holdings will be worth about 247.8 in February 2025. The stock is currently trading at 237.28. This means that the stock has a potential upside of +4.41%.
Issuer Forecast Upside
Wallstreet Target Price 246.1 3.7%
Analysts Target Price 247.2 4.2%
ValueRay Target Price 247.8 4.4%